2018
Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)
Cannon CP, McGuire DK, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Charbonnel B, Shih WJ, Gallo S, Masiukiewicz U, Golm G, Cosentino F, Lauring B, Terra SG, Investigators V. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV). American Heart Journal 2018, 206: 11-23. PMID: 30290289, DOI: 10.1016/j.ahj.2018.08.016.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBlood GlucoseBridged Bicyclo Compounds, HeterocyclicCardiovascular DiseasesDiabetes Mellitus, Type 2Dose-Response Relationship, DrugDouble-Blind MethodEuropeFemaleFollow-Up StudiesGlycated HemoglobinHumansIncidenceMaleMiddle AgedProspective StudiesSodium-Glucose Transporter 2 InhibitorsSurvival RateTreatment OutcomeUnited StatesConceptsAtherosclerotic cardiovascular diseaseCardiovascular outcome trialsCV deathHeart failureComposite outcomeOutcome trialsMajor adverse CV eventsStage 3 kidney diseaseType 2 diabetes mellitusEfficacy of ertugliflozinVERTIS-CV trialAdverse CV eventsNonfatal myocardial infarctionDouble-blind placeboPeripheral arterial diseaseCoronary artery diseasePeripheral arterial systemCV eventsERTugliflozin effIcacyNonfatal strokeRenal safetyDiabetes durationBaseline characteristicsRenal deathSerum creatinine
2017
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PF, Soran H, White H, Wright RS, Vrablik M, Yunis C, Shear CL, Tardif JC. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. New England Journal Of Medicine 2017, 376: 1527-1539. PMID: 28304242, DOI: 10.1056/nejmoa1701488.Peer-Reviewed Original ResearchMeSH KeywordsAntibodiesAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsCardiovascular DiseasesCholesterol, LDLDouble-Blind MethodFemaleFollow-Up StudiesHumansHypercholesterolemiaInjections, SubcutaneousLipidsMaleMiddle AgedPCSK9 InhibitorsProprotein Convertase 9Risk FactorsTreatment FailureConceptsMajor cardiovascular eventsPrimary end pointHigh-risk patientsLDL cholesterol levelsCardiovascular eventsPlacebo groupCholesterol levelsMajor adverse cardiovascular eventsLow-density lipoprotein cholesterolEnd pointSubtilisin kexin type 9Safety of bococizumabAdverse cardiovascular eventsHigh cardiovascular riskNonfatal myocardial infarctionLow-risk patientsInjection site reactionsHumanized monoclonal antibodyDifferent entry criteriaLonger duration trialsShort-duration trialsCardiovascular efficacyNonfatal strokeUrgent revascularizationCardiovascular death
2013
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI. Oral Apixaban for the Treatment of Acute Venous Thromboembolism. New England Journal Of Medicine 2013, 369: 799-808. PMID: 23808982, DOI: 10.1056/nejmoa1302507.Peer-Reviewed Original ResearchConceptsAcute venous thromboembolismConventional therapy groupPrimary efficacy outcomeVenous thromboembolismMajor bleedingConventional therapyApixaban groupRelevant nonmajorEfficacy outcomesRecurrent symptomatic venous thromboembolismOral factor Xa inhibitorsFixed-dose regimenPrincipal safety outcomeSymptomatic venous thromboembolismDouble-blind studyFactor Xa inhibitorsOral apixabanAdverse eventsComposite outcomeRelative riskThromboembolismXa inhibitorsApixabanSafety outcomesBleeding
2004
Calcium homeostasis and disorders of calcium metabolism during pregnancy and lactation
Masiukiewicz U, Insogna K. Calcium homeostasis and disorders of calcium metabolism during pregnancy and lactation. In Medical Complications During Pregnancy, 6th edition. Burrow G, Duffy T, editors.Books
2003
Maternal calcium and skeletal homeostasis during pregnancy and lactation
Masiukiewicz U, Insogna K. Maternal calcium and skeletal homeostasis during pregnancy and lactation. In The DeGrooth Textbook of Endocrinology, DeGrooth L, Burrow G, editors. Endotext.org., 2003.Books
2002
Role of the interleukin-6/interleukin-6 soluble receptor cytokine system in mediating increased skeletal sensitivity to parathyroid hormone in perimenopausal women.
Insogna K, Mitnick M, Pascarella J, Nakchbandi I, Grey A, Masiukiewicz U. Role of the interleukin-6/interleukin-6 soluble receptor cytokine system in mediating increased skeletal sensitivity to parathyroid hormone in perimenopausal women. Journal Of Bone And Mineral Research 2002, 17 Suppl 2: n108-16. PMID: 12412787.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnimalsBone and BonesBone ResorptionCollagenCollagen Type ICytokinesDisease Models, AnimalEstrogensFemaleFollow-Up StudiesHumansHyperparathyroidismInterleukin-6MenopauseMiceMiddle AgedOsteoporosis, PostmenopausalParathyroid HormonePeptidesPostmenopausePredictive Value of TestsPremenopauseReceptors, Interleukin-6Reference ValuesRetrospective StudiesConceptsIL-6/ILInterleukin-6Skeletal sensitivityPerimenopausal periodPrimary hyperparathyroidismPerimenopausal womenCytokine systemInterleukin-6 soluble receptorSerum IL-6 valuesEstrogen-deficient stateUrine N-telopeptideInterleukin-6/interleukinAction of PTHGroup of patientsIL-6 valuesSerum IL-6/ILEstrogen modulatesIL-6sRIL-6sR.Perimenopausal groupUrine NTXPremenopausal womenSkeletal complicationsCytokine profileExaggerated releaseEvidence that the IL-6/IL-6 Soluble Receptor Cytokine System Plays a Role in the Increased Skeletal Sensitivity to PTH in Estrogen-Deficient Women
Masiukiewicz US, Mitnick M, Gulanski BI, Insogna KL. Evidence that the IL-6/IL-6 Soluble Receptor Cytokine System Plays a Role in the Increased Skeletal Sensitivity to PTH in Estrogen-Deficient Women. The Journal Of Clinical Endocrinology & Metabolism 2002, 87: 2892-2898. PMID: 12050269, DOI: 10.1210/jcem.87.6.8577.Peer-Reviewed Original ResearchConceptsEstrogen-deficient womenIL-6/ILSkeletal sensitivityIL-6IL-6sREstrogen deficiencyCytokine systemIL-6 soluble receptorUrine N-telopeptideAction of PTHPrevious animal studiesNTx excretionPTH infusionPostmenopausal womenSerum calciumN-telopeptideCytokine productionTNF-alphaExaggerated increaseIL-1betaHormonal statusBaseline valuesSoluble receptorAnimal studiesColony-stimulating factor-1
2001
IL-6 Negatively Regulates IL-11 Production in Vitro and in Vivo
Nakchbandi I, Mitnick M, Masiukiewicz U, Sun B, Insogna K. IL-6 Negatively Regulates IL-11 Production in Vitro and in Vivo. Endocrinology 2001, 142: 3850-3856. DOI: 10.1210/en.142.9.3850.Peer-Reviewed Original ResearchCirculating levels of IL-6Levels of IL-6IL-11IL-6Circulating levelsBone resorptionSteady state mRNA levelsOsteoclast formationFive-day infusionHuman PTH-(1-84Pretreatment of cellsIL-11 levelsResponse to PTHIL-11 productionIncreased osteoclast formationIL-6 levelsPTH-(1-84Saos-2 cellsParathyroid adenomectomyDown-regulationProduction in vitroPrimary hyperparathyroidismPTH excessProduction in vivoSerum levelsCytokines in Primary Hyperparathyroidism
10. Nakchbandi I, Masiukiewicz U, Mitnick M, Grey A, Insogna K. Cytokines in Primary Hyperparathyroidism. In The Parathyroids 2nd edition. J. Belizikan, M Levine, R Marcus eds. Academic Press. 411-421, 2001Books
2000
Estrogen Modulates Parathyroid Hormone-Induced Interleukin-6 Production in Vivo and in Vitro*
Masiukiewicz U, Mitnick M, Grey A, Insogna K. Estrogen Modulates Parathyroid Hormone-Induced Interleukin-6 Production in Vivo and in Vitro*. Endocrinology 2000, 141: 2526-2531. DOI: 10.1210/en.141.7.2526.Peer-Reviewed Original ResearchCirculating levels of IL-6Levels of IL-6PTH-induced bone resorptionEstrogen-deficient stateIL-6Circulating levelsIL-6 productionPTH infusionEstrogen withdrawalBone resorptionResponse to PTH infusionChronic PTH excessEstrogen-replete conditionsTreated with PTHBone turnover markersInfusion of PTHBone resorption markersResponse to PTHEffect of PTHAbsence of estrogenRelease of IL-6Short-term infusionEstrogen-treated animalsInterleukin (IL)-6Collagen cross-linking
1999
Papillary Thyroid Carcinoma Metastatic to the Pituitary Gland
Masiukiewicz US, Nakchbandi IA, Stewart AF, Inzucchi SE. Papillary Thyroid Carcinoma Metastatic to the Pituitary Gland. Thyroid 1999, 9: 1023-1027. PMID: 10560958, DOI: 10.1089/thy.1999.9.1023.Peer-Reviewed Original ResearchConceptsPituitary glandThyroid carcinomaSymptoms of hypopituitarismThyroid carcinoma metastaticWithdrawal of levothyroxineRecombinant human TSHPapillary thyroid carcinomaPituitary metastasisCarcinoma metastaticLevothyroxine withdrawalHuman TSHRare associationThyrotropin productionBiochemical manifestationsMetastasisCarcinomaGlandWithdrawalAssociationPanhypopituitarismHypopituitarismLevothyroxineMetastaticHypothyroidismPatientsA Role for Interleukin-6 in Parathyroid Hormone-Induced Bone Resorption in Vivo1
Grey A, Mitnick M, Masiukiewicz U, Sun B, Rudikoff S, Jilka R, Manolagas S, Insogna K. A Role for Interleukin-6 in Parathyroid Hormone-Induced Bone Resorption in Vivo1. Endocrinology 1999, 140: 4683-4690. DOI: 10.1210/en.140.10.4683.Peer-Reviewed Original ResearchBiochemical markers of bone resorptionMarkers of bone resorptionPTH-induced bone resorptionParathyroid hormoneBone resorptionInterleukin-6Biochemical markersPTH infusionResponse to PTH infusionCirculating levels of interleukin-6Action of PTH in vivoMarkers of bone formationResponse to PTHEffect of parathyroid hormoneLevels of interleukin-6Neutralization of interleukin-6Associated with markedly lower levelsParathyroid hormone-induced bone resorptionPTH in vivoBone resorbing actionPTH-induced changesRelease of calciumInterleukin-6 productionCytokine interleukin-6Paracrine factor(sHyperthyroidism in Pregnancy: Diagnosis and Treatment
Masiukiewicz US, Burrow GN. Hyperthyroidism in Pregnancy: Diagnosis and Treatment. Thyroid 1999, 9: 647-652. PMID: 10447008, DOI: 10.1089/thy.1999.9.647.Peer-Reviewed Original ResearchConceptsCauses of thyrotoxicosisAutoimmune Graves' diseaseFetal outcomesMenstrual irregularitiesGraves' diseaseModerate hyperthyroidismTherapeutic dilemmaPregnant womenTherapeutic optionsPeak incidenceReproductive yearsHyperthyroidismFourth decadePregnancyDiseaseWomenThyrotoxicosisCurrent reviewDiagnosisGestationIncidenceSymptomatology
1998
The role of parathyroid hormone in the pathogenesis, prevention and treatment of postmenopausal osteoporosis
Masiukiewicz US, Insogna KL. The role of parathyroid hormone in the pathogenesis, prevention and treatment of postmenopausal osteoporosis. Aging Clinical And Experimental Research 1998, 10: 232-239. PMID: 9801733, DOI: 10.1007/bf03339657.Peer-Reviewed Original ResearchConceptsParathyroid hormonePostmenopausal womenPrimary hyperparathyroidismBone lossSecondary hyperparathyroidismAnabolic therapyPostmenopausal osteoporosisBone massVitamin D. Parathyroid hormoneDaily subcutaneous administrationRecent therapeutic trialsVitamin D metabolismTrabecular bone massTherapeutic trialsD metabolismBone turnoverBone resorptionSurgical correctionSubcutaneous administrationHyperparathyroidismVivo effectsSingle agentTissue responsivenessSustained increaseCortical sitesProlonged use of etomidate infusion to control severe hypercortisolemia in a patient with Cushing's disease
Masiukiewicz U, Inzucchi SE. Prolonged use of etomidate infusion to control severe hypercortisolemia in a patient with Cushing's disease. Proceedings of the 80th Meeting of the Endocrine Society. pg 507, 1998.Books
1988
[Clinical pharmacology of flecainide].
Rewerski W, Walczak F, Nyznyk M, Dorociak A, Skorupska U. [Clinical pharmacology of flecainide]. Polski Tygodnik Lekarski (Warsaw, Poland : 1960) 1988, 43: 1161-5. PMID: 3150783.Peer-Reviewed Original ResearchPropafenone in reentry tachycardia
Walczak F, Gottner B, Skorupska (Masiukiewicz) U, Nyznyk M, Wysocki M, Rembelska H, Jedynak Z, Rewerski W. Hoffman M. Propafenone in reentry tachycardia. Pharmacol Clin. 4:26, 1988Peer-Reviewed Original ResearchInternational Symposium on Clinical Pharmacology, Propafenone in Reentry Tachycardia
Walczak F, Gotter B, Skorupska (Masiukiewicz) U, Nyznyk M, Wysocki M, Rembelska H, Jedynak Z, Reweski W, Hoffman M. International Symposium on Clinical Pharmacology, Propafenone in Reentry Tachycardia. Wroclaw, Poland, 1988Books
1987
Einfluss des Propafenones auf Reentry Tachycardien
Walczak F, Gotter B, Skorupska (Masiukiewicz) U, Nyznyk M, Wysocki M, Rembelska H, Poplawska W, Jedynak Z, Hoffman M. Einfluss des Propafenones auf Reentry Tachycardien. XIII Kongres der Geselshaft fur Kardiologie und Angiologie der, Germany, Gera, 1987.Books